Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Background In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)—mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR).Methods A multicenter phase two study was performed in wo...

Повний опис

Бібліографічні деталі

Автори:	Linda Mileshkin, Elizabeth Barnes, Tarek Meniawy, Kristy Robledo, Michael Friedlander, Geraldine Goss, Jermaine Coward, Yoland Antill, Michelle Cummins, Sally Baron-Hay, Martin R Stockler, Catherine Shannon, Philip Beale, Peey-Sei Kok, Deborah Smith, Sonia Yip, Amanda Spurdle, Yeh Chen Lee, Janine Lombard, John Andrews
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMJ Publishing Group 2021-06-01
Серія:	Journal for ImmunoTherapy of Cancer
Онлайн доступ:	https://jitc.bmj.com/content/9/6/e002255.full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!